FAAH deficiency promotes energy storage and enhances the motivation for food

International Journal of Obesity

Volumn 34, Issue 3, 2010, Pages 557-568

  Tourio C ^a   Oveisi, F ^b   Lockney, J ^b   Piomelli, D ^b   Maldonado, R ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anandamide; Body weight; Fatty acid amide hydrolase; Food intake; Lipid turnover; Oleoylethanolamide

Indexed keywords

ADIPONECTIN; ANANDAMIDE; FATTY ACID AMIDASE; LEPTIN; N OLEOYLETHANOLAMINE; RIMONABANT; TRIACYLGLYCEROL; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR AFFECTING AGENT; ENDOCANNABINOID; FAT INTAKE; FATTY-ACID AMIDE HYDROLASE; OLEIC ACID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENERGY BALANCE; ENERGY CONSERVATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPOTHALAMUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SMALL INTESTINE; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DARKNESS; DEFICIENCY; DRUG EFFECTS; EATING; FAT INTAKE; INSTRUMENTAL CONDITIONING; KNOCKOUT MOUSE; LIPID METABOLISM; METABOLISM; MOTIVATION; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOSITY; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BODY WEIGHT; CONDITIONING, OPERANT; DARKNESS; DIETARY FATS; EATING; ENDOCANNABINOIDS; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTIVATION; OBESITY; OLEIC ACIDS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; TRIGLYCERIDES; CANNABINOID RECEPTOR MODULATORS;

MUS;

EID: 77949542479     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.262     Document Type: Article

References (39)

1. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007; 23: 507-517.
2. Colombo G, Agabio R, Díaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: L113-L117.
3. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
4. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
5. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 200; 134: 1151-1154.
6. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557.
7. Thornton-Jones ZD, Vickers SP, Clifton PG. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consum-matory responses for food. Psychopharmacology (Berl) 2005; 179: 452-460.
8. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24: 2708-2715.
9. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-867.
10. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le FG, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
11. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
12. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psycho-pharmacology (Berl) 1999; 143: 315-317.
13. Mahler SV, Smith KS, Berridge KC. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmaco-logy 2007; 32: 2267-2278.
14. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83-87.
15. Ueda N, Yamamoto S. Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat 2000; 61: 19-28.
16. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, Mackie K et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 2007; 282: 1518-1528.
17. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci 2005; 62: 708-716.
18. Guzman M, Lo VJ, Fu J, Oveisi F, Blazquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 2004; 279: 27849-27854.
19. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 2007; 120 (Suppl 1): S18-S24.
20. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-9376.
21. Gaetani S, Oveisi F, Piomelli D. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuro-psychopharmacology 2003; 28: 1311-1316.
22. Giuffrida A, Rodŕiguez de Fonseca F, Nava F, Loubet-Lescoulie P, Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol 2000; 408: 161-168.
23. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005; 313: 352-358.
24. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res 2008; 36: 135-145.
25. Fu J, Gaetani S, Oveisi F, Lo VJ, Serrano A, Rodríguez de Fonseca F et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003; 425: 90-93.
26. Rodŕiguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J et al. An anorexic lipid mediator regulated by feeding. Nature 2001; 414: 209-212.
27. Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006; 30 (Suppl 1): S7-S12.
28. Kohsaka A, Laposky AD, Ramsey KM, Estrada C, Joshu C, Kobayashi Y et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab 2007; 6: 414-421.
29. Valenti M, Vigano D, Casico MG, Rubino T, Steardo L, Parolaro D et al. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol Life Sci 2004; 61: 945-950.
30. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuro-pharmacology 2005; 49: 646-652.
31. Huang H, cuna-Goycolea C, Li Y, Cheng HM, Obrietan K, van den Pol AN. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci 2007; 27: 4870-4881.
32. Osei-Hyiaman D, DePetrillo M, Harvey-White J, Bannon AW, Cravatt BF, Kuhar MJ et al. Cocaine-and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 2005; 81: 273-282.
33. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
34. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571-580.
35. Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, Hoareau L et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 2007; 152: 676-690.
36. Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 2005; 16: 381-388.
37. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2006; 137: 337-361.
38. Fu J, Kim J, Oveisi F, Astarita G, Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R45-R50.
39. Motter AL, Ahern GP. TRPV1-null mice are protected from diet-induced obesity. FEBS Lett 2008; 582: 2257-2262.